Abstract 9P
Background
To evaluate clinicopathological features and prognosis in women with mucinous breast cancer (MBC), distinguishing between pure (PMC) and mixed (MMC) subtype.
Methods
A retrospective analysis of all 358 women with MBC treated at Vietnam National Cancer hospital from June 2015 to December 2020. PMC was defined by ≥ 90% mucinous components.
Results
We identified 358 women with MBC (245 PMC and 113 MMC) representing 2.7% of all 13,254 breast cancer patients. The proportion of stage I, II, III and IV were 34.9%, 50.8%, 10.4% and 3.9% respectively. 95.3% of patients were hormone receptor positive. The rate of HER2 overexpression is 12%, and only 1.4% of patients was treated with anti-HER2. 193 patients (53.9%) had chemotherapy (CT), including 55 patients (15.4%) treated in neoadjuvant setting. Among those received neoadjuvant CT, only 3 patients (5.5%) achieved pCR. Meanwhile, the rates of partial response, stable disease and progressive disease were 50.8%, 38.2% and 5.5% respectively. PMC patients were older (54.4±13.3 vs 51.1±13.1 years), had lower Ki67 expression, lower incidence of nodal metastasis (N+) than MMC patients (p values <0.05). At median follow-up of 58 months, the 5-year overall survival rate of non-metastatic patients was 86.6%. Univariate analysis revealed that significant factors for poorer OS were MMC subtype (p=0.02), large tumor size (T) (p<0.001), N+ (p<0.001), HER2 overexpression (p<0.001), PR negative (p=0.02), and high Ki67 (p=0.02). Multivariate analysis showed nodal metastasis (N+) to be the most significant prognostic factor (HR=3.3; 95%CI 1.5-7.1), followed by high T stage (HR=2.9; 95%CI 1.4-6.3), HER2 overexpression (HR=2.5; 95%CI 1.2-5.3) and MMC subtype (HR=1.9; 95%CI 1.0-3.9). Amongst 245 patients with stage T1-2N0M0, 40.8% of those treated with CT related to worse overall survival (5-year OS 88.0% vs 95.6%, p=0.04).
Conclusions
The majority of MBC are luminal subtypes and associated with good prognosis. Poor prognostic factors of women with MBC are high T, N stage, HER2 overexpression and MMC subtype. Chemotherapy in stage T1-2N0M0 brings a worse survival outcome compared to endocrine therapy. Given the low response rate to neoadjuvant CT, upfront surgery is appropriate for MBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract